Idiopathic Pulmonary Fibrosis (IPF)

Trial Objective

The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF.

GERD & IPF

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.1553 or complete the form below.

Who Can Participate

Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate.


Estimated Time Commitment

5 visits over a 6-month period, visits are every 3 months

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

Boehringer Ingelheim

Age

40-95


Gender

Any Gender

Principal Investigators


Request More Information

*
*
*
*